findmyKOL
Clinical trialNCT03687125TerminatedPhase 1/PHASE2Interventional

Tinostamustine Conditioning and Autologous Stem Cell

SponsorMundipharma-EDO GmbHEnrollment6Multiple Myeloma ProgressionMultiple Myeloma With Failed RemissionMultiple Myeloma in Relapse
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Phase 1 The primary objectives of Phase 1 of this study are to: * Establish the safety, toxicity, and maximum tolerated dose (MTD) of the tinostamustine conditioning regimen. * Identify the recommended Phase 2 dose (RP2D) of tinostamustine for use in the Phase 2 portion of the study. The secondary objective of Phase 1 of this study is to: \- Investigate the pharmacokinetics (PK) of tinostamustine.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Norway
  • Oslo Myeloma Center, Oslo University Hospital

    Oslo, Norway

Switzerland
  • Universitatsspital Basel

    Basel, Switzerland

  • Universitatsspital Bern

    Bern, Switzerland

  • Department of Clinical Research Oncology/hematology, Kantonsspital St. Gallen

    Sankt Gallen, Switzerland

  • University Hospital Zurich

    Zurich, Switzerland

United States
  • University of Alabama

    Birmingham, Alabama, United States

  • University of Kansas Medical Center Kansas City

    Kansas City, Kansas, United States

  • Memorial Sloan Kettering Cancer Centre

    New York, New York, United States

  • Carolinas Healthcare System

    Charlotte, North Carolina, United States

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, United States

  • University of Texas Md Anderson Cancer Center

    Houston, Texas, United States

  • Froedtert & Medical College of Wisconsin, Cancer Center - Froedtert Hospital

    Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Tinostamustine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
15 Oct 2018
Primary completion
17 Apr 2019
Completion
17 Apr 2019
Last update posted
18 Jun 2021
Registered enrollment
6
Registry id
NCT03687125

Cross-registrations

EU-CTR / CTIS (EudraCT)2018-001907-35
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.